For nearly three decades, the Agency for Healthcare Research and Quality (AHRQ) has served as the federal government’s home for research focused on a seemingly simple question: How can we make health care safer, more effective, more affordable, and more accessible for patients in the United States?
AHRQ traces its roots to the Agency for Health Care Policy and Research, established in 1989. In 1999, the Healthcare Research and Quality Act reauthorized the agency and established its current name and mission. Today, AHRQ is part of the U.S. Department of Health and Human Services (HHS), with a mandate that spans patient safety research, health services research, data and analytics, and the development of tools and resources that can help translate evidence into better care.
AHRQ’s role is to help answer the questions that come next: Does a treatment actually reach the patients who need it? How can hospitals prevent avoidable harm? How can health systems deliver better care at lower cost? How can new technologies, including telehealth and artificial intelligence, improve care?
This mission puts AHRQ in a distinctive position within the federal research enterprise. Its work intersects with that of agencies including the Centers for Medicare & Medicaid Services (CMS), the Centers for Disease Control and Prevention (CDC), and the National Institutes of Health (NIH), as well as state health agencies and health systems, and with researchers across the country.
For years, AHRQ’s work has provided an evidence base for improving how health care is delivered across the country. Today, that infrastructure is under extraordinary strain. AHRQ has recently faced a series of disruptions to its staffing, grantmaking, and operations that have contributed to uncertainty about the future of federally funded health services research.
In its September meeting, the Society for Women’s Health Research (SWHR) Policy Advisory Council was joined by Josh Caplan, MA, MPP, Director of Government Affairs at AcademyHealth. For six years, Caplan has been leading the Friends of AHRQ. During the September Policy Advisory Council meeting, he provided details on the extraordinary challenges currently faced by the agency.
AHRQ on Defense
According to Caplan, the last 18 months have presented an unprecedented challenge for AHRQ and the research community that depends on it.
The scale of disruption at the agency became particularly visible in the fall of 2025 and into 2026. AHRQ lost approximately 80% of its staff in 2025, including all of the workforce responsible for reviewing grants and working directly with grantees. For a grantmaking agency, the consequences are significant: who is responsible for reviewing applications, managing awards, communicating with researchers, and overseeing the research Congress has funded?
It was also around this time that AHRQ stopped issuing new research awards and, according to reporting at the time, stopped issuing continuation funding for existing projects. Researchers were left waiting for expected funding installments, sometimes for months, without clear information about when—or whether—their awards would move forward. By April 2026, reports indicated that AHRQ had spent none of the roughly $215 million Congress had appropriated for the agency to spend on health costs, quality, and outcomes research for the fiscal year, while $80 million in FY2025 funding had been returned to the Treasury. The Government Accountability Office found that the $80 million was illegally withheld and the Agency was obligated to spend it in FY2025.
So, while individual grants were delayed, the agency’s capacity to administer its own research portfolio was also simultaneously dramatically reduced.
On July 15, 2026, approximately 150 AHRQ grantees received notices that their ongoing grants would not receive additional funding. Lawmakers and research organizations subsequently raised concerns that the notices were largely identical and did not substantively address the individual grant-specific considerations cited in the relevant regulations. The affected research covers a broad range of health care questions, including those that appeared to overlap with areas AHRQ had identified as priorities, such as research on training rural health care workers to respond to maternal emergencies, improving access to home dialysis, reducing patient falls in rural hospitals, improving patient safety through telehealth, and developing better approaches to chronic pain treatment.
The consequences extend beyond individual principal investigators. Multi-year research programs depend on continuity. Graduate students can lose funding. Research staff can be laid off, and institutions can be forced to halt projects or abandon future work. When a research program is forced to halt midway through answering a health research question, the knowledge it was designed to produce may never reach patients or providers.
The situation took another major turn in September 2026, when the Office of Management and Budget (OMB) announced that it would seek to cancel nearly $810 million in congressionally appropriated funding, over half of which would be stripped from HHS, including$28 million from AHRQ. Federal law allows the administration to temporarily cancel funding only if it tells Congress in advance and gives Congress 45 days to respond; otherwise, the money must be restored. However, providing notice at the end of a fiscal year for funding that expires on September 30 effectively denies Congress a meaningful opportunity to respond, raising questions about whether such a move exceeds what is legally permissible under “pocket rescission.” The Government Accountability Office found that this was an illegal withholding.
AcademyHealth is documenting the impact of the canceled grants through its Research Interrupted tracker, and SWHR continues to monitor federal actions as they evolve.
Congress Weighs In
Questions about federal funding authority have moved to the center of the debate.
Congress appropriates funds to federal agencies for specific purposes. When appropriated funds are withheld, transferred, or otherwise prevented from being used, questions can arise under federal appropriations and impoundment law. Members of Congress have argued that the administration’s handling of AHRQ funding amounts to an unlawful impoundment of funds Congress appropriated for health services research. These legal questions remain contested.
In August 2026, members of both the House and Senate publicly challenged the cancellation of AHRQ grants. In the House, a letter from House Democrats noted that Congress had appropriated $345.38 million for AHRQ in FY2026 and argued that the cancellations raised concerns about the agency’s statutory responsibilities and federal appropriations law. Meanwhile, Democratic senators have urged HHS to rescind the cancellations. Their letter described disruptions to nearly 200 research programs across nearly 30 states and highlighted the loss of AHRQ staff and the resulting impact on grant administration. Senators Dave McCormick (R-PA) and John Fetterman (D-PA) separately pressed HHS about canceled AHRQ grants affecting researchers at their local hospitals and universities. On September 16, Senators Patty Murray (D-WA) and Tammy Baldwin (D-WI) wrote to HHS Secretary Kennedy, Jr. seeking information about the department’s plans for AHRQ funding, requesting information specific to interagency agreements, AHRQ activities, and grantees through the end of the fiscal year.
The timing is significant. With fiscal year (FY) 2027 appropriations discussions underway, lawmakers are confronting the question of how much money AHRQ should receive and whether the agency has the staffing and institutional capacity necessary to carry out the work Congress has directed it to do.
Advocacy in Motion
For Caplan and the Friends of AHRQ coalition, this is where advocacy becomes particularly important.
Health services research can sometimes feel removed from its bedside impacts, but the questions AHRQ-funded researchers investigate help determine what care patients experience when they enter the health care system. Understanding the importance of this work, the Friends of AHRQ coalition has been dedicated to defending the agency, the reliability of its funding, and making visible what can be lost when the federal infrastructure supporting health services research is weakened.
Caplan has been leading the Friends of AHRQ during a period in which the coalition has had to respond in real time to rapidly changing circumstances, and, as Caplan put it, a time when confidence in the federal research enterprise is being compromised.
When researchers receive federal awards, they build teams, hire staff, enroll participants, collect data, and make long-term commitments based on the expectation that appropriated funding will be administered according to the terms of those awards. When that continuity breaks down, it can affect whether institutions are willing to build programs around federal research, whether early-career researchers remain in the field, and whether patients ultimately benefit from the knowledge those programs were designed to produce. “It’s patient care, patient lives, that are being lost… They’re not able to access all the biomedical research coming out of NIH, so there are real impacts because we’re not trying to get to patients,” Caplan said.
As Congress works through FY 2027 appropriations, advocates, researchers, health systems, patients, and SWHR will be watching what happens with AHRQ’s funding, staffing, and grant portfolio and will be advocating for the sufficient, steady funding on which federal research relies.